tool name

close
tool goes here

New FDA rules require lower sleep aid dosages

The Food and Drug Administration is requiring makers of Ambien and similar sleeping pills to lower the dosage of their drugs, based on studies suggesting patients face a higher risk of injury due to morning drowsiness.

Published: Jan. 11, 2013 at 12:05 a.m. PST
0 comments

The Food and Drug Administration is requiring makers of Ambien and similar sleeping pills to lower the dosage of their drugs, based on studies suggesting patients face a higher risk of injury due to morning drowsiness.

New research shows that the drugs remain in the bloodstream at levels high enough to interfere with alertness and coordination. Regulators are ordering drug manufacturers to cut the dose of the medications in half for women, who process the drug more slowly. Doses will be lowered from 10 milligrams to 5 milligrams for regular products, and 12.5 milligrams to 6.25 milligrams for extended-release formulations.

The FDA is recommending but not requiring that manufacturers apply these lower doses to men as well.

JOIN THE DISCUSSION | Register here

We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.

CONTESTS

Similar stories

  • FDA has safety concerns with Merck insomnia drug

    Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

  • FDA panel backs experimental Merck insomnia drug

    A federal panel of medical experts said that an experimental insomnia drug from Merck & Co. Inc. appears safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty driving.

  • Ranbaxy halts generic Lipitor production

    Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into dozens of batches of the drug that were recalled in November.

  • FDA: Experimental insomnia drug also has side effects

    Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

  • PNNL analyses: Is risk from plastic water bottles inflated?

    A controversial component of plastic bottles and canned food linings is present in far too small amounts in most people's bodies to cause suspected health effects, according to Pacific Northwest National Laboratory analyses.

    "My findings are consistent with FDA's (Food and Drug Administration) and European Food Safety Authority's conclusions that BPA is safe as currently used," said toxicologist Justin Teeguarden, a senior scientist at the Department of Energy's national laboratory in Richland.

    BPA, or bisphenol A, has the potential to mimic the sex hormone estrogen if blood and tissue levels are high enough, disrupting that part of the endocrine, or hormone, system.